Kelas : 3EB24
NPM: 29214956
Review Article 4
Limitations and opportunities for immune checkpoint inhibitors in
pediatric malignancies
Highlights
• Immune checkpoint inhibitors (ICI) have achieved a
great success in adult cancers.
• There is growing interest in ICI for pediatric
malignancies.
• There are significant barriers for successful
pediatric integration of ICI.
• Combination with other treatment modalities could be
a promising option.
Abstract
Immune checkpoint inhibitors (ICI) have shown great
promise in a wide spectrum of adult solid and hematological malignancies,
achieving objective tumor responses and prolonging survival. However, there is
limited clinical success amongst pediatric patients. In this review, we
summarize the current understanding of ICI and present an up-to-date overview
of recent and ongoing clinical trials of ICI in pediatric malignancies. In
addition, we will discuss immunologic and clinical difficulties in this young
population, as well as future prospects for combination of ICI with other
immune-based and conventional treatments.
Keywords
- Immune checkpoint inhibitor;
- Immunotherapy;
- Programmed death receptor-1 (PD-1);
- Programmed death-ligand 1 (PD-L1);
- Cytotoxic
T lymphocyte antigen-4 (CTLA-4)
Tidak ada komentar:
Posting Komentar